Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy.

The purpose of the study was to identify vulnerable patients with head and neck cancer undergoing concurrent chemoradiation therapy who are susceptible to higher treatment-related adverse effects and have poorer treatment tolerance.